CureVac Shareholders Face Pivotal Acquisition Vote
Veröffentlicht: 03.11.2025 um 17:19 Uhr, Redaktion boerse-global.de
The fate of CureVac hangs in the balance as shareholders approach a critical decision point regarding BioNTech’s acquisition proposal. With a tender offer now officially underway, investors must weigh a substantial share-exchange deal that would fundamentally reshape the mRNA biotechnology landscape.
BioNTech has formally initiated the exchange process, proposing that CureVac shareholders receive approximately $5.46 in BioNTech shares for each CureVac share they hold. This transaction, valued at $1.25 billion overall, represents a significant strategic pivot for both organizations. The deal has already garnered substantial support, with shareholders representing more than 50% of CureVac’s equity indicating their approval, including major investor dievini Hopp BioTech holding.
However, the arrangement includes complex Read more...
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
